Biotum

Leaflet attached to the packaging: information for the user

Biotum, 500 mg, powder for solution for injection

Ceftazidime

Read the leaflet carefully before taking the medicine, as it contains important information for the patient.

• Keep this leaflet, you may need to read it again.
• If you have any further questions, ask your doctor or nurse.
• This medicine has been prescribed for a specific person. Do not pass it on to others. The medicine may harm another person, even if their symptoms are the same.
• If the patient experiences any side effects, including any not listed in this leaflet, they should tell their doctor or nurse. See section 4.

Table of contents of the leaflet

• 1. What is Biotum and what is it used for
• 2. Important information before taking Biotum
• 3. How to take Biotum
• 4. Possible side effects
• 5. How to store Biotum
• 6. Contents of the packaging and other information

1. What is Biotum and what is it used for

Biotum is an antibiotic used in adults and children (including newborns). It has a bactericidal effect on bacteria that cause infections. It belongs to a group of medicines called cephalosporins.

Biotum is used to treat severe bacterial infections:

• lower respiratory tract, including lungs
• lungs and bronchi in patients with cystic fibrosis
• brain (meningitis)
• ear
• urinary tract
• skin and soft tissues
• abdominal cavity and abdominal walls (peritonitis)
• bones and joints.

Biotum can also be used:

• to prevent infections during transurethral resection of the prostate in men
• to treat patients with a low white blood cell count (neutropenia) who have a fever due to a bacterial infection.

2. Important information before taking Biotum

When not to take Biotum

• If the patient is allergic to ceftazidime or any of the other ingredients of this medicine (listed in section 6).
• If the patient has ever had a severe allergic reaction to any other antibiotic (penicillins, monobactams, and carbapenems), as they may also be allergic to Biotum.

➢
If the patient suspects that they are affected by the above circumstances, they should inform their doctor before starting treatment with Biotum.
Do not give the patient Biotum.

Warnings and precautions

Before starting treatment with Biotum, the patient should discuss it with their doctor or nurse.
Attention should be paid to whether the patient experiences any special symptoms during treatment with Biotum, such as allergic reactions, nervous system disorders, and gastrointestinal disorders, including diarrhea. This will reduce the risk of possible problems. See "Symptoms to watch out for" in section 4. If the patient has ever had an allergic reaction to other antibiotics, they may also be allergic to Biotum.
Severe skin reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP), have been reported with ceftazidime. If the patient experiences any of the symptoms associated with these severe skin reactions, described in section 4, they should contact their doctor immediately.
Blood and urine tests
Biotum may change the results of urine sugar content tests and blood tests known as the Coombs test. If the patient is to have such tests:

• Tell the person taking the samplethat the patient has taken Biotum.

Biotum and other medicines

Tell the doctor about all medicines the patient is taking, or has recently taken, and about any medicines the patient plans to take.
The patient should not take Biotum without consulting their doctor if they are also taking:

• the antibiotic chloramphenicol
• an antibiotic from the group called aminoglycosides, such as gentamicin or tobramycin
• diuretic tablets containing furosemide.

➢
If the above circumstances apply to the patient, tell the doctor
in charge.

Pregnancy and breastfeeding

If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult their doctor before taking this medicine.
The doctor will assess whether the benefits of taking Biotum during pregnancy and breastfeeding outweigh the risks to the child.

Driving and using machines

Biotum may cause side effects that affect the ability to drive or operate machinery, such as dizziness (see section 4). The patient should not drive or operate machinery unless they are sure that they have not experienced these side effects.

Biotum contains sodium

Each vial of Biotum 500 mg contains 30 mg of sodium. This corresponds to 1.5% of the maximum recommended daily intake of sodium in the diet for adults.
The medicine contains 60 mg of sodium (the main component of common salt) per gram of powder. This corresponds to 3% of the maximum recommended daily intake of sodium in the diet for adults. This should be taken into account in patients with reduced kidney function and in patients controlling their sodium intake.
Preparation of the medicine for administration - see the section "Information intended exclusively for healthcare professionals" at the end of the leaflet. When calculating the total sodium content in the prepared dilution, the sodium from the diluent should be taken into account. For accurate information on the sodium content in the solution used to dilute the medicine, refer to the patient information leaflet for the diluent used.

3. How to take Biotum

This medicine should always be taken as directed by the doctor. In case of doubt, consult the doctor.
Biotum is usually administered by a doctor or nurse.It can be administered by drip(intravenous infusion) or as an injection directly into a vein or intramuscular injection.
Biotum is prepared by a doctor or nurse using water for injections or another suitable infusion fluid.

Usual dose

The doctor will decide on the appropriate dose of Biotum for the patient, taking into account the severity and type of infection, the patient's intake of other antibiotics, their body weight, age, and kidney function.

Newborns and infants (0-2 months old)

For every 1 kg of infant body weight, 25-60 mg of Biotum is administered over 24 hours in two divided doses.
Infants (over 2 months old) and childrenwith a body weight of less than 40 kg
For every kg of infant or child body weight, 100-150 mg of Biotum is administered over 24 hours in three divided doses. Maximum 6 g per day.
Adults and adolescentswith a body weight of 40 kg or more
1-2 g of Biotum three times a day. Maximum 9 g per day.

Patients over 65 years old

The daily dose should not be higher than 3 g per day, especially in patients over 80 years old.

Patients with kidney disease

The patient may receive a different dose than usual. The doctor or nurse will decide on the dose of Biotum to be administered to the patient, depending on the severity of the kidney disease. The doctor will closely monitor the patient and may order more frequent kidney function tests.

Use of a higher dose of Biotum than recommended

In case of accidental use of a higher dose of Biotum than prescribed, contact the doctor in charge or go to the nearest hospital immediately.

Missing a dose of Biotum

If the patient has not taken an injection, it should be administered as soon as possible.
Do not take a double dose (two injections at the same time) to make up for a missed dose, but take the next dose at the usual time.

Stopping treatment with Biotum

Do not stop taking Biotum without the doctor's advice.
If the patient has any further doubts about taking this medicine, they should consult their doctor or nurse.

4. Possible side effects

Like all medicines, Biotum can cause side effects, although not everybody gets them.

Symptoms to watch out for

➢
The severe side effects described below have occurred in a small number of people, but their exact frequency is unknown (the frequency cannot be determined from the available data).

If the patient experiences any of the following symptoms, they should contact their doctor immediately:

• Severe allergic reaction. Symptoms are: raised, itchy rash swelling, sometimes of the face or lips, which can cause difficulty breathing.
• Red spots on the torso, spots resembling a target or circle, often with central blisters, peeling of the skin, ulcers in the mouth, throat, nose, genitals, and eyes. These severe skin rashes can be preceded by fever and flu-like symptoms (Stevens-Johnson syndrome, toxic epidermal necrolysis).
• Widespread rash, high body temperature, and enlarged lymph nodes (DRESS or drug hypersensitivity syndrome).
• Red, peeling, widespread rash with nodules under the skin and blisters and concurrent fever. Symptoms usually occur at the beginning of treatment (acute generalized exanthematous pustulosis).
• Nervous system disorders: tremors, seizures, and sometimes coma. These disorders have occurred in patients who have received too high doses, especially in patients with kidney disease.

Common side effects

May occur in more than 1 in 10patients:

• diarrhea
• swelling and redness along the vein
• red, raised rash on the skin, which may itch
• pain, burning, swelling, or inflammation at the injection site.

➢

If any of the above symptoms worry the patient, they should tell their doctor.

Common side effects that may be seen in blood tests:

• increased number of one type of white blood cell (eosinophilia)
• increased number of platelets, which are involved in blood clotting
• increased activity of liver enzymes.

Uncommon side effects

May occur in more than 1 in 100patients:

• inflammation of the intestines, which can cause abdominal pain or diarrhea that may contain blood
• thrush - fungal infections of the mouth or vagina
• headache
• dizziness
• abdominal pain
• nausea or vomiting
• fever and chills.

➢

Tell the doctor if the patient experiences any of the above symptoms

from the above list.
Uncommon side effects that may be seen in blood tests:

• decreased number of white blood cells
• decreased number of platelets (cells involved in blood clotting)
• increased levels of urea, nitrogen, or creatinine in the blood.

Rare side effects

May occur in more than 1 in 10,000patients:

• inflammation or kidney failure.

Other side effects

Other side effects that have occurred in a small number of patients, but the exact frequency is unknown:

• tingling
• unpleasant taste in the mouth
• yellowing of the whites of the eyes and skin.

Other side effects that may be seen in blood tests:

• red blood cells break down too quickly
• increased number of one type of white blood cell in the blood
• significant decrease in the number of white blood cells.

Reporting side effects

If side effects occur, including any not listed in this leaflet, the patient should tell their doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products
Al. Jerozolimskie 181C
02-222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help to gather more information on the safety of the medicine.

5. How to store Biotum

Store the medicine at a temperature not exceeding 25°C. Protect from light.
The prepared solution can be stored for 24 hours in the refrigerator, i.e., at a temperature between 2°C and 8°C.
Store the medicine out of sight and reach of children.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month.
The inscription on the packaging after the abbreviation EXP means the expiry date, and after the abbreviation Lot means the batch number.
Medicines should not be disposed of via wastewater or household waste. Ask the pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.

6. Contents of the packaging and other information

What Biotum contains

• The active substance of the medicine is ceftazidime. Each vial contains 500 mg of ceftazidime in the form of a pentahydrate buffered with sodium carbonate.
• The other ingredient is: sodium carbonate.

What Biotum looks like and what the pack contains

White or light yellow powder in a glass vial, sealed with a rubber stopper and protected by an aluminum cap or aluminum cap with a hood, in a cardboard box.
The packaging contains 1 or 10 vials.
Not all pack sizes may be marketed.

Marketing authorization holder and manufacturer

Marketing authorization holder

Pharmaceutical Works POLPHARMA S.A.
Pelplińska 19, 83-200 Starogard Gdański
phone: +48 22 364 61 01

Manufacturer

Pharmaceutical Works POLPHARMA S.A.
Pelplińska 19, 83-200 Starogard Gdański
Pharmaceutical Works POLPHARMA S.A.
Duchnice Production Plant
Ożarowska 28/30, 05-850 Ożarów Mazowiecki

Date of last revision of the leaflet:

---------------------------------------------------------------------------------------------------------------------------

Information intended exclusively for healthcare professionals

Biotum, 500 mg, powder for solution for injection

Ceftazidime
The pressure in Biotum vials of any size is lower than atmospheric pressure. When dissolving the powder, the pressure increases due to the release of carbon dioxide. Small carbon dioxide bubbles in the prepared solution can be ignored.
Instructions for preparing the medicine for use
Refer to the table of added volumes and resulting concentrations, which may be useful when partial doses are needed.

The color of the solution ranges from light yellow to amber, depending on the concentration, type of solvent, and storage conditions. If the recommended conditions are met, the variability of the solution color does not adversely affect the effectiveness of the product.
Preparation of the solution for rapid injection

• 1. Pierce the stopper with a needle and inject the recommended volume of solvent into the vial. To puncture the stopper, use a needle with a diameter not larger than 0.8 mm (21 G in the Gauge [G] scale). Insert the needle at a 90° angle, in the center of the marked field, as shown in the following diagram:

The negative pressure inside the vial may facilitate the entry of the solvent. Withdraw the needle with the syringe.

• 2. Shake until dissolved: carbon dioxide is released and a clear solution is obtained within 1 to 2 minutes.
• 3. Invert the vial. Holding the syringe plunger in the fully depressed position, pierce the vial stopper with the needle and draw the entire volume of the solution into the syringe (the increased pressure in the vial will facilitate this). Keep the needle in the solution to avoid drawing in air. The solution drawn into the syringe may contain small carbon dioxide bubbles. These solutions can be administered directly into a vein or into an intravenous infusion set, if the patient is receiving intravenous fluids. Ceftazidime is compatible with most commonly used intravenous fluids.